If your screening results show that you have two or more diabetes-related autoantibodies and there’s not a prevention study that’s right for you at this time, you can still make a lasting contribution to T1D research.
When you sign up for monitoring, you’ll come to a TrialNet location once or twice a year for follow up. And, when new studies become available, you’ll be among the first to know!
You may qualify for monitoring if you participated in Pathway to Prevention screening and tested positive for two or more diabetes-related autoantibodies.
You will go to your most convenient TrialNet location within 3 months of screening for your first monitoring visit. After that, you will come in once or twice a year, depending on your test results.
At each monitoring visit, we will do a blood test to check your level of risk for T1D. You will also take an oral glucose tolerance test (OGTT). It involves drinking about a cup (less for children) of a sweet glucose drink in 5 minutes. Some people may feel a little sick to their stomachs.
Two hours after you drink the glucose, we will draw another blood sample. During the test, you will need to sit quietly and rest. At times, we may also take blood samples we store and use for other studies to learn more about T1D. Samples are always small and completely safe for your age and weight.
At some visits, we will ask about your diet and physical activity and do a brief physical exam. Some people will develop T1D while participating in monitoring. Our tests will likely show this before you have any symptoms.
For people taking part in T1D research, the risk of diabetic ketoacidosis (DKA) at diagnosis drops from 30% to less than 4%. DKA is a serious condition that can be life-threatening. With early notification, you will be able to see your doctor and start taking insulin before you feel sick.
There may be a study for newly diagnosed T1D that is right for you.